Reata Pharmaceuticals, Inc. [●] Shares Class A Common Stock ($0.001 par value per share) Underwriting AgreementUnderwriting Agreement • February 8th, 2016 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • New York
Reata Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [●] shares of Class A common stock, $0.001 par value per share (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [●] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singu
ContractLicense Agreement • February 8th, 2016 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • New York
SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED. THESE REDACTED TERMS HAVE BEEN MARKED IN THIS EXHIBIT WITH THREE ASTERISKS [***]. AN UNREDACTED VERSION OF THIS EXHIBIT HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
COLLABORATION AGREEMENT between REATA PHARMACEUTICALS, INC. and ABBOTT PHARMACEUTICALS PR LTD. Dated as of December 9, 2011Collaboration Agreement • February 8th, 2016 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS COLLABORATION AGREEMENT (this “Agreement”) is entered into as of December 9, 2011 (the “Effective Date”) by and between REATA PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 (“Reata”), and ABBOTT PHARMACEUTICALS PR LTD., a Bermuda corporation having its principal place of business at 2 KM 58.2, Cruce Davila, Barceloneta 00617, Puerto Rico (“Abbott”). Reata and Abbott are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
